- Home
- CELZ vs TOVX Comparison
CELZ vs TOVX Comparison
Compare CELZ & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELZ | TOVX |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 7.3M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | CELZ | TOVX |
|---|---|---|
| Price | $2.00 | $0.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 160.7K | ★ 11.0M |
| Earning Date | 11-07-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $0.17 |
| 52 Week High | $6.90 | $1.75 |
Technical Indicators
Market Signals| Indicator | CELZ | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 43.61 |
| Support Level | $1.68 | $0.19 |
| Resistance Level | $2.09 | $0.22 |
| Average True Range (ATR) | 0.28 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 51.81 | 19.64 |
Price Performance
Historical ComparisonAbout CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.